Genmab A (GMAB) Other Operating Expenses (2018 - 2026)

Genmab A (GMAB) has reported Other Operating Expenses for 5 consecutive years, with -$84.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 15.15% year-over-year to -$84.0 million; the trailing twelve-month figure through Jun 2026 stood at -$405.0 million (down 6.86% YoY), and the FY2025 full-year result was -$238.0 million, down 159.69% from the prior year.
• Other Operating Expenses eased to -$84.0 million in Q2 2026 per GMAB's latest filing, from -$65.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at -$2.0 million in Q2 2023 and bottomed at -$157.0 million in Q3 2025.
• Historically, Other Operating Expenses has averaged -$69.5 million across 4 years, with a median of -$65.0 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Other Operating Expenses plunged 790.54% in 2024, then gained 15.15% in 2026.
• Over 4 years, Other Operating Expenses stood at -$33.0 million in 2023, then slumped by 333.33% to -$143.0 million in 2024, then decreased by 9.79% to -$157.0 million in 2025, then soared by 46.5% to -$84.0 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$84.0 million, -$65.0 million, and -$157.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.